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generation DES]
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Background: The aim of this study was to compare the efﬁcacy and safety of
everolimus-eluting stents (EES) in treatment of patient with coronary artery disease
(CAD) as compared to other drug eluting stents (DES): paclitaxel eluting stents (PES),
sirolimus eluting stents (SES), zotarolimus eluting stents (ZES) and biolimus A9
eluting stents (BES).
Methods: Katowice Registry included 1916 consecutive patients treated with EES
as well as non-EES group (PES, SES, ZES, BES). Primary efﬁcacy end-point was
Major Adverse Cardiac and Cerebrovascular event (MACCE) deﬁned as death,
stroke or repeat-revascularization at 1-year follow-up. Safety end-point was stent
thrombosis.
Results: Registry included [UA 1502 (78%), NSTEMI 238 (15%), STEMI
131(7%)]. There were 770 (35%) patients in EES group and 1246 (65%) in non-EES
group. There were no differences in the prevalence of diabetes (36% vs. 38%
p¼0.47), chronic kidney disease (18% vs. 17% p¼0.32) as well as complexity of
CAD measured by SYNTAX [SX] score between EES and non-EES. Use of EES
group was comparable to non-EES in terms of risk of death [HR¼0.82 (95%CI
0.48–1.40), p¼0.55), myocardial infarction [HR¼0.75 (95%CI 0.47–1.19), p¼0.26],
target vessel revascularization [HR¼0.90 (95%CI 0.46–1.26), p¼0.58], stroke
[HR¼0.51 (95%CI, 0.14–1.81), p¼0.43] or MACCE [HR¼0.80 (95%CI, 0.60–
1.06), p¼0.28] at 1-year follow-up. Use of EES was associated with lower rate of
acute as wel as subacute stent thrombosis than non-EES [0% vs. 0.6 and 0% vs.
0.2%, respectively, p¼0.02).
Conclusions: Nonrestricted use of EES was associated with lower rate of early ST as
compared to other DES. The 1-year incidence of MACCE was similar in EES in
comparison to other DES.
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Background: aim of this study was to evaluate the sex differences in the long-term
clinical outcomes and safety of patients treated with ﬁrst- and second generation DES.
Methods: The Katowice-Zabrze Registry included 1916 consecutive patients treated
with either ﬁrst- (paclitaxel, sirolimus eluting; 34%) or second-generation (everolimus,
zotarolimus, biolimus A9, 66%) DES. Primary efﬁcacy end-point was Major Adverse
Cardiac and Cerebrovascular event (MACCE) deﬁned as death, stroke or repeat-
revascularization were recorded at 1-year follow-up. Safety endpoint was stent
thrombosis.
Results: Registry included [UA 1502 (78%), NSTEMI 238(15%), STEMI 131 (7%)].
There were 680 (35.5%) females and 1236 (64.5%) males. Women were older
(65.99.8 vs. 61.89.8 years, p< 0.001) and had higher prevalence of diabetes
(50.1% vs. 30.4%, p< 0.001) and chronic kidney disease (24.7% vs. 13.2%, p<
0.001). Conversely, multivessel coronary artery disease was more frequent in males
(30.1% vs 21.9% p< 0.001). There were no differences in complexity of coronary
artery disease between males and female as measured by SYNTAX. There was no
difference in ratio of early stent thrombosis (0.5% vs 0.6%, p¼0.88) but women had
more often bleeding complications after PCI that required urgent blood transfusion
(1.7% vs. 0.4%, p¼0.005) and had longer hospitalization time (6 IQR 4-7 vs 5 IQR 3-
6 days p< 0.001). Univariable Cox regression analysis revealed that women had
similar outcome as men in terms of a risk of death [HR¼1.08 (95%CI 0.64–1.82),
p¼0.880), myocardial infarction [HR¼0.72 (95%CI 0.47–1.09), p¼0,149], target
vessel restenosis [HR¼1.05; (95%CI 0.75–1.46), p¼0.849],stroke [HR¼1.38 (95%JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/SteCI, 0.43–4.41), p¼0,792] and MACCE [HR¼0.97 (95%CI, 0.75–1.28), p¼0.977] at
1-year follow-up. There were no differences between sexes in MACCE when forst and
second generaton DES were analyzed separately.
Conclusions: Despite higher risk proﬁle, women treated with DES are not at increased
risk of death or MACCE as compared to men at 1-year follow-up. There is however an
increased risk of periprocedural bleeding complications in women.
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Background: The PE Plus Post-Approval Study (PE Plus PAS) was designed to
examine outcomes among patients treated with advanced generation, everolimus-
eluting, platinum chromium PROMUS Element stents (Boston Scientiﬁc, Natick,
MA) over 5 years in a ‘real-world setting’. This is the ﬁrst report of results from this
large multicenter post-approval study.
Methods: PE Plus PAS was a prospective, open-label, multicenter observational study
at 52 enrolling sites in the US. Follow-up was at 30 days, 6 months, and 1 year, and
will continue annually through 5 years. The primary endpoint was 12-month cardiac
death or myocardial infarction (CD/MI) in ‘PLATINUM-like’ patients pooled from
PE Plus PAS and PE PROVE and patients from the PLATINUM Workhorse (WH)/
Small Vessel (SV) trials. The PLATINUM-like patient cohort was deﬁned as all
patients that met the criteria for enrollment in the Platinum WH/SV trials. A 1-sided z-
approximation test was applied to determine if the 12-month CD/MI rate met the
prespeciﬁed performance goal of 3.2% (expected rate of 2.2% + delta of 1.0%). Rates
of major adverse cardiac events (MACE), the individual components of MACE as
well as ARC deﬁnite/probable stent thrombosis will be analyzed in the overall PE Plus
PAS patient population in addition to the prespeciﬁed Platinum-like group. Incidence
of longitudinal stent compression conﬁrmed by core laboratory assessment was also
assessed.
Results: Among 2684 enrolled patients, 70% were male, mean age was 6411 years,
37% had medically treated diabetes, and more than three-quarters were treated for
hyperlipidemia and hypertension. At baseline, mean lesion length among 3595 treated
lesions was 1710 mm and mean reference vessel diameter was 2.90.5 mm. Plat-
inum-like patients accounted for 29% of the overall PE Plus PAS patient population.
Conclusions: The primary endpoint results from the PE Plus PAS will be available at
the time of the presentation and will lend insight into the performance and safety of the
PROMUS Element Plus everolimus-eluting stent at 1 year in everyday clinical
practice.
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Background: Previous trials showed that, compared to 1st generation drug eluting
stent (DES), coronary artery by-pass surgery (CABG) signiﬁcantly reduces major
cardiac adverse events (MACCE) in patients (pts) with multiple vessel disease
(MVD).
Methods: Between March 2013 and January 2014 we included 225 pts undergoing
DES implantation in 15 sites in Argentina. The registry followed all regulatory process
and was monitored by an external independent committee. Primary endpoint of
ERACI 4 Registry was to assess the incidence of MACCE [death, myocardial
infarction (MI) cerebrovascular accident (CVA) and unplanned target vessel revas-
cularization (TVR)] in pts with MVD using Firebird-2 rapamycin eluted stents
(MicroPort, Shangai) vs. ERACI 3 population (1st generation DES and CABG arms)
at 30 days, 6 and 12 months of follow-up. All pts have an indication for myocardial
revascularization and lesions  70% in 2 or 3 coronary arteries and/or unprotected left
main disease (ULM). Exclusion criteria were ejection fraction  35%, recent STEMI
(< 72 hours), DES in an intention to treat artery, lesion diameter  2.5 mm or
contraindications for dual antiplatelet therapy (DAPT). Stent thrombosis was also
analyzed. The only DES allowed was Firebird-2.nts - Drug-eluting: Registries B167
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comResults: Mean age was 64 +/- 11.2 years, 84.4% males, 30.2% diabetics and 59.6%
had unstable angina at inclusion. 54.3% with 3 vessels and ULM, 1.8 +/- 0.3 Firebird-
2 per pt was implanted. Clinical success was accomplished in 100%. At discharge all
pts received DAPT. Complete 6 months follow-up results are reported in Table. In pts
with diabetes, Firebird-2 group also showed a beneﬁt in MACCE compared to ERACI
3-DES p¼0.02 and ERACI 3-CABG p¼0.04.6 months outcome
ERACI 4
ERACI 3-
DES
ERACI 3-
CABG
ERACI 4
vs ERACI
3-DES
ERACI 4
vs ERACI
3- CABG
N patients 225 225 225
Death 1 (0.4%) 6 (2.7%) 15 (6.7%) 0.05 <0.001
Myocardial
Infarction (MI)
1 (0.4%) 5 (2.2%) 14 (6.2%) 0.1 0.001
Non-fatal
Cerebrovascular
accident (CVA)
0 (0%) 1 (0.4%) 2 (0.9%) 0.31 0.15
Death/MI/CVA 2 (0.9%) 9 (4.0%) 31 (13.8%) 0.03 <0.001
Target vessel
revascularization
(TVR)
2 (0.9%) 13 (5.8%) 5 (2.2%) 0.004 0.25
MACCE (Death/
MI/CVA/TVR)
4 (1.8%) 17 (7.6%) 36 (16.0%) 0.004 <0.001Conclusions: At 6 months this multicenter and prospective registry showed that
Firebird 2 had a remarkable low incidence of MACCE and death/MI/CVA either
compared to CABG or 1st DES arms,Firebird 2 also had lower TVR rate than 1st
DES.
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Background: The ION Registry assessed clinical outcomes for the thin-strut, ION
(TAXUS Element) Paclitaxel-Eluting Platinum Chromium Coronary Stent System
(Boston Scientiﬁc, Natick, MA) in unselected patients at 40 sites in the United
States. Two-year “real world” results with this stent have not been previously
reported.
Methods: This prospective, open-label registry enrolled 1120 consenting all-
comer patients treated with the ION stent for any indication at each site. Follow-
up was at discharge, 30 and 180 days, and annually to 5 years. The primary
endpoint was the 1-year rate of cardiac death or MI in PERSEUS-like patients (ie,
patients who met the enrollment criteria for the pivotal PERSEUS trial; JACC
2010;56:264–71). Per protocol, the primary endpoint result from the ION registry
was also combined with the EU post-approval registry (TE-PROVE), which
enrolled 306 PERSEUS-like patients, and the PERSEUS WH/SV populations
(N¼1166).
Results: Among 1111 patients who received a study stent, most (70.3%, 781/
1111) were male, with a mean age of 64.111.0 years, and 316 were PERSEUS-
like. At 1-year, clinical follow-up or death were recorded in 92.1% (1023/1111).
The primary endpoint of cardiac death or MI at 1 year occurred in 2.1% (6/292)
of PERSEUS-like patients in ION and 2.3% (40/1729) patients in the combined
analysis. The upper 1-sided 95% CI for the combined analysis was 2.9%, which
was signiﬁcantly less than the prespeciﬁed performance goal of 7.6% (P<
0.001). Additional 1-year clinical endpoint rates were 9.4% (97/1028) MACE
(deﬁned as cardiac death, MI, TVR), 2.0% (21/1028) cardiac death (0.4% related
to ION stent), 3.0% (31/1028) MI (1.9% related to ION stent), 6.8% (70/1028)
TVR (4.9% related to ION stent), and 2.1% (22/1028) ARC deﬁnite/probable ST
(2.0% related to ION stent).
Conclusions: The 1-year results of the ION US Post-Approval Study conﬁrm the
safety and effectiveness of the ION stent for the treatment of coronary artery disease in
everyday clinical practice. Two-year overall results and results from selected subsets
of this real-world population (diabetes, small vessels, long lesions) will be available
for the ﬁrst time at TCT 2014.B168 JACC Vol 64/11/Suppl B j SeTCT-579
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Background: It remains unclear whether there are differences in the safety and ef-
ﬁcacy outcomes between Cobalt Chronium (CoCr-EES) and Platinum Chronium
everolimus-eluting stents (PtCr-EES).
Methods: From the Interventional Cardiology Research In-Cooperation Society-
Drug-Eluting Stents Registry, we identiﬁed 6065 consecutive patients who received
CoCr-EES (3080 patients) and PtCr-EES (2985 patients). We compared major
adverse cardiac events (MACE) which was deﬁned using a composite measure
consisting of death, nonfatal myocardial infarction, or target vessel revascularization
(TVR) with the use of propensity-score matching in the overall cohort according to
type of stents.
Results: At 2-years of clinical follow-up, the 2 study groups (2510 patients for each
propensity-score matched group) did not differ signiﬁcantly in crude risk of the
MACE (12.0% for CoCr-EES versus 11.6% for PtCr-EES; HR, 0.954; 95% CI, 0.81 –
1.13, p¼0.581). There was also no differences between the stent groups in the risks of
the individual component of death (HR, 1.083; 95% CI, 0.786 – 1.492, p¼0.624), MI
(HR, 0.972; 95% CI, 0.770 – 1.228, p¼0.812), and TVR (HR, 0.798; 95% CI, 0.598 –
1.065, p¼0.125). The risk of cerebrovascular event (HR, 0.914; 95% CI, 0.566 –
1.477, p¼0.714) and deﬁnite stent thrombosis (HR, 1.000; 95% CI, 0.290 – 3.454,
p¼1.000) were also similar between the two groups.Conclusions: The use of CoCr-EES and PtCr-EES showed similar rates of safety and
efﬁcacy outcomes with regard to death, MI, stent thrombosis and TVR.
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Background: The TE-PROVE post-market registry has enrolled 1014 patients at 37
sites in the EU to evaluate real-world clinical outcomes for patients receiving the
paclitaxel-eluting, platinum chromium TAXUS Element stent (Boston Scientiﬁc,
Natick, MA). This is the ﬁrst report of 2-year outcomes with the TAXUS Element
stent in everyday clinical practice.
Methods: The primary endpoint of overall and study stent-related target vessel failure
(TVF, deﬁned as cardiac death, and target vessel-related MI and reintervention [TVR])
at 1 year post-implantation was 6.0% (59/987), of which 3.7% (37/9874) was
considered related to the study stent (Tamburino et al, TCT 2013). Follow-up in TE-
PROVE will continue annually through 5 years. Secondary endpoints included the
components of TVF, all-cause mortality, and ARC deﬁnite/probable stent thrombosis.
An independent Clinical Events Committee adjudicated all events for relatedness to
the study stent.
Results: At baseline, 75.0% (760/1014) of patients were male, mean age was
65.110.8 years, 25.5% (259/1014) had medically treated diabetes, mean lesion
length was 19.812.0mm, and mean reference vessel diameter was 3.10.5 mm. At 2ptember 13–17, 2014 j TCT Abstracts/Stents - Drug-eluting: Registries
